“It is a great pleasure to be able to offer U.S. patients access to SIMLANDI, the only citrate-free, high-concentration interchangeable biosimilar to Humira. We look forward to increasing the availability of cost-effective quality biosimilars in the U.S., as...
The most frequent adverse events were infections and injection-site reactions. Adalimumab was also assessed in an open-label mul- ticenter study conducted in 32 children aged 2–4 years (or older than 4 years with body weight <15 kg) with moderate to severe polyarticular JIA.50 The ...
The most frequent adverse events were infections and injection-site reactions. Adalimumab was also assessed in an open-label mul- ticenter study conducted in 32 children aged 2–4 years (or older than 4 years with body weight <15 kg) with moderate to severe polyarticular JIA.50 The ...